Effect of Steroids on Gene Expression in the Healthy Smokers Lungs
Chronic Obstructive Pulmonary Disease (COPD)
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease (COPD) focused on measuring COPD, inhaled steroids, bronchodilator, gene expression, smoker's lungs
Eligibility Criteria
Inclusion Criteria:
Group A and B
- All study individual should be enrolled in Weill-IRB protocol #0005004439 entitled "Evaluation of the Lungs of Normal (Smokers, Ex-smokers, Non-Smokers) Individuals with Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy"
- All study subjects should be able to provide informed consent
- Current smokers with 15-to 40 pack-year history
- All study individuals should be healthy as per protocol #0005004439 entitled "Evaluation of the Lungs of Normal (Smokers, Ex-smokers, Non-Smokers) Individuals with Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy"
Group C
- All study individual should be enrolled in Weill-IRB protocol #0005004439 entitled "Evaluation of the Lungs of Normal (Smokers, Ex-smokers, Non-Smokers) Individuals with Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy"
- All study subjects should be able to provide informed consent
- All study individual should be healthy as per protocol #0005004439 entitled "Evaluation of the Lungs of Normal (Smokers, Ex-smokers, Non-Smokers) Individuals with Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy"
Exclusion Criteria:
Group A and B
- Smokers intending to quit smoking in the next 14 days.
- Individuals already receiving any lung related inhalers
- Females who are pregnant or nursing
Group C
Exclusion Criteria:
- Non-smokers who intend to start smoking in the next 14 days
- Individuals already receiving any lung related inhalers
- Females who are pregnant or nursing
Sites / Locations
- Weill Cornell Medical College
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
No Intervention
No Intervention
treatment with inhaled beclomethasone
Control - healthy smokers
control - healthy non-smokers
The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
Group B will act as control and include healthy smokers who receive no treatment.
Group C will act as control and include healthy non-smokers who receive no treatment.